Analyst Price Targets — SYK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 12:54 pm | — | UBS | $400.00 | $381.83 | TheFly | Stryker price target raised to $400 from $386 at UBS |
| February 2, 2026 11:25 am | — | Barclays | $469.00 | $369.56 | TheFly | Stryker price target raised to $469 from $462 at Barclays |
| January 30, 2026 2:34 pm | Mike Matson | Needham | $454.00 | $365.62 | TheFly | Stryker price target raised to $454 from $448 at Needham |
| January 30, 2026 12:26 pm | — | Robert W. Baird | $437.00 | $369.02 | TheFly | Stryker price target lowered to $437 from $450 at Baird |
| January 30, 2026 10:23 am | Ryan Zimmerman | BTIG | $412.00 | $354.30 | StreetInsider | Stryker (SYK) PT Raised to $412 at BTIG |
| January 9, 2026 11:50 am | Lee Hambright | Bernstein | $465.00 | $367.21 | TheFly | Stryker price target raised to $465 from $450 at Bernstein |
| January 9, 2026 10:48 am | — | Goldman Sachs | $399.00 | $367.21 | TheFly | Stryker price target lowered to $399 from $418 at Goldman Sachs |
| January 6, 2026 10:12 am | — | Raymond James | $418.00 | $348.79 | TheFly | Stryker upgraded to Outperform from Market Perform at Raymond James |
| January 5, 2026 2:55 pm | — | Evercore ISI | $390.00 | $347.69 | TheFly | Stryker price target lowered to $390 from $405 at Evercore ISI |
| November 14, 2025 2:33 pm | Richard Newitter | Truist Financial | $400.00 | $366.38 | TheFly | Stryker price target raised to $400 from $392 at Truist |
Latest News for SYK
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing…
Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued…
Davis R M Inc. lifted its position in shares of Stryker Corporation (NYSE: SYK) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 138,732 shares of the medical technology company's stock after purchasing an additional 2,512 shares during the
Bahl and Gaynor Inc. lessened its holdings in Stryker Corporation (NYSE: SYK) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 279,006 shares of the medical technology company's stock after selling 6,281 shares during the
111 Capital bought a new stake in Stryker Corporation (NYSE: SYK) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,763 shares of the medical technology company's stock, valued at approximately $1,391,000. Other institutional investors have also bought
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.